Literature DB >> 10587656

Survivin' cell-separation anxiety.

J C Reed, S I Reed.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10587656     DOI： 10.1038/70227

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN： 1465-7392            Impact factor:   28.824


× No keyword cloud information.
  14 in total

Review 1.  The Survivin saga goes in vivo.

Authors:  J C Reed
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 2.  Survivin and leukemia.

Authors:  Xiu Li Cong; Zhong Chao Han
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

3.  Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter.

Authors:  Qiuying Cheng; Xiang Ling; Andrew Haller; Takahito Nakahara; Kentaro Yamanaka; Aya Kita; Hiroshi Koutoku; Masahiro Takeuchi; Michael G Brattain; Fengzhi Li
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

4.  Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines.

Authors:  Fengzhi Li; Xiang Ling; Huayi Huang; Lisa Brattain; Pasha Apontes; Jianguo Wu; Lise Binderup; Michael G Brattain
Journal:  Oncogene       Date:  2005-02-17       Impact factor: 9.867

5.  Mitosis-specific anchoring of gamma tubulin complexes by pericentrin controls spindle organization and mitotic entry.

Authors:  Wendy C Zimmerman; James Sillibourne; Jack Rosa; Stephen J Doxsey
Journal:  Mol Biol Cell       Date:  2004-05-14       Impact factor: 4.138

6.  An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI).

Authors:  Xiang Ling; Fengzhi Li
Journal:  Am J Transl Res       Date:  2013-03-28       Impact factor: 4.060

7.  A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.

Authors:  Xiang Ling; Shousong Cao; Qiuying Cheng; James T Keefe; Youcef M Rustum; Fengzhi Li
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

Review 8.  Antisense therapy in clinical oncology: preclinical and clinical experiences.

Authors:  Ingo Tamm; Mandy Wagner
Journal:  Mol Biotechnol       Date:  2006-07       Impact factor: 2.860

9.  The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.

Authors:  Y Somnay; S Lubner; H Gill; J B Matsumura; H Chen
Journal:  Cancer Gene Ther       Date:  2016-09-16       Impact factor: 5.987

10.  Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils.

Authors:  Frank Altznauer; Sibylla Martinelli; Shida Yousefi; Christine Thürig; Inès Schmid; Edward M Conway; Martin H Schöni; Peter Vogt; Christoph Mueller; Martin F Fey; Uwe Zangemeister-Wittke; Hans-Uwe Simon
Journal:  J Exp Med       Date:  2004-05-17       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.